In contrast, we found small effects of sclerostin antibody treatment on the skeletal phenotype of the Col1a1Jrt/+ mouse, a model of severe OI caused by a dominant splice site mutation in Col1a112. The gene discussed is SOST; the disease is osteogenesis imperfecta.